Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Carcinoma, Renal Cell 35Carcinoma, Hepatocellular 17Neoplasm Metastasis 15Prostatic Neoplasms 13Neoplasms 9Neuroendocrine Tumors 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 6Brain Neoplasms 6Sarcoma, Ewing 5Sarcoma 5Osteosarcoma 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Transitional Cell 5Recurrence 4Pancreatic Neoplasms 4Multiple Myeloma 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Pheochromocytoma 2Paraganglioma 2Neurofibroma, Plexiform 2Melanoma 2

Interventions

AZD 6244 4trametinib 2cabozantinib 2Imatinib Mesylate 2pirfenidone 1peginterferon alfa-2b 1nilotinib 1binimetinib 1Vinblastine 1Methotrexate 1Liquid Biopsy 1Gadolinium DTPA 1Fluorodeoxyglucose F18 1Cryotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neurofibroma, Plexiform × cabozantinib × Clear all
NCT06502171 2026-03-12

NF113

University of Alabama at Birmingham

Phase 1 Not yet recruiting
30 enrolled
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed
45 enrolled 10 charts
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡